{"changes":[],"country":"CH","description":"Windward Bio is a Basel clinical-stage biotech developing long-acting antibodies for asthma, COPD, and other type-2 immune diseases. Lead drug WIN378 is a six-month-dosed anti-TSLP antibody in Phase 2/3. The company has raised over $365M across Series A and crossover financings since 2025.","domain":"indwardbio.com","employees":null,"founded":2025,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":46.521827,"lng":6.632702,"location":"Lausanne","name":"Windward Bio","rounds":[{"amountQuarantined":false,"amountUsd":165000000,"currency":"USD","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"indwardbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"indwardbio.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://indwardbio.com"},{"fact":"description","publisher":"indwardbio.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://indwardbio.com"}],"stage":"series-b+","techStack":[],"totalRaisedUsd":165000000,"updatedAt":"2026-05-07"}